Invenomic Capital Management LP Makes New $6.78 Million Investment in Haemonetics Corporation $HAE

Key Points

• Invenomic Capital Management LP has acquired 106,730 shares of Haemonetics Corporation, valued at approximately $6.78 million, representing about 0.21% of the company’s stock.
• Haemonetics recently reported a Q1 EPS of $1.10, surpassing estimates, despite a 4.4% year-over-year decline in revenue.
• Institutional investors hold 99.67% of Haemonetics' stock, with several firms increasing their stakes in the company during the first quarter.

Invenomic Capital Management LP acquired a new position in Haemonetics Corporation (NYSE:HAE - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 106,730 shares of the medical instruments supplier's stock, valued at approximately $6,783,000. Invenomic Capital Management LP owned approximately 0.21% of Haemonetics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP grew its stake in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in Haemonetics during the 1st quarter valued at about $65,000. KBC Group NV grew its holdings in Haemonetics by 19.9% during the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. Vise Technologies Inc. grew its holdings in Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares during the last quarter. Finally, CWC Advisors LLC. grew its holdings in Haemonetics by 7.4% during the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after purchasing an additional 212 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Up 0.5%

Shares of NYSE:HAE traded up $0.26 during trading hours on Friday, hitting $54.34. The company's stock had a trading volume of 627,638 shares, compared to its average volume of 974,669. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of 16.62, a P/E/G ratio of 1.00 and a beta of 0.39. The firm's fifty day moving average price is $66.04 and its 200 day moving average price is $65.77. Haemonetics Corporation has a 52 week low of $50.68 and a 52 week high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping the consensus estimate of $1.01 by $0.09. The firm had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. Haemonetics's revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the topic of several analyst reports. JMP Securities reiterated a "market outperform" rating and set a $100.00 price target on shares of Haemonetics in a report on Tuesday, May 20th. Needham & Company LLC reiterated a "buy" rating and set a $68.00 price target (down from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Barrington Research lowered their price objective on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Finally, Mizuho lowered their price objective on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $85.18.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.